FDA Accepts Resubmission for RP1 Oncolytic Immunotherapy Plus Nivolumab in PD-1–Refractory Melanoma

FDA Accepts Resubmission for RP1 Oncolytic Immunotherapy Plus Nivolumab in PD-1–Refractory Melanoma

OncoDaily Party Berlin 2025: A Night Where Oncology Met Energy

OncoDaily Party Berlin 2025 ESMO

100 Influential People in Oncology 2025 - Nominations are Open!

100 Influential People in Oncology 2025

Iza-bren (EGFR×HER3 bispecific ADC) 303 Study: Late-breaking ESMO presentation, The Lancet publication, and press-conference Q&A highlights

iza-bren egfrxher3 bispecific press release

Zihai Li: First-In-Human Anti-GARP CAR-T Trial for Patients With Relapsed GBM

Zihai Li

Katy Rezvani: Comprehensive Overview of Engineered Natural Killer Cells for Cancer Therapy

Katy Rezvani

International Cardio-Oncology Society Introduced the GCOS 2025 Social Media Ambassador Team

International Cardio-Oncology Society Introduced the GCOS 2025 Social Media Ambassador Team

Enrique Soto: New ASCO Global Guideline on Geriatric Assessment

Enrique Soto

Lung cancer